Novonordisk.com - Levemir Clinical Data for HCPs
Novo Nordisk country sites
USA
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Canada
Chile
China
Croatia
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hungary
India
Iraq
Ireland
Israel
Italy
Japan
Korea (Republic)
Latvia
Lebanon
Lithuania
Mexico
Netherlands
New Zealand
Norway
Pakistan
Poland
Portugal
Romania
Russian Federation
Serbia
Slovak Republic
Slovenia
South Africa
Spain
Sweden
Switzerland
Syria
Taiwan
Thailand
Turkey
Ukraine
United Kingdom
Other Novo Nordisk sites
Changing diabetes
DAWN study
Hagedorn Research Institute
Diabetes4Patients
Diabetes Barometer
Changing diabetes bus
Media prize
World diabetes day
School challenge
Improve Control
HRT for HCPs
HRT for women
HRT congresses & symposia
Healthcare Professionals
Patients
Investors
Media
R&D
Jobs
Sustainability
About us
Overview
Pharmaceuticals
Victoza®
Levemir®
NovoMix® 30
NovoRapid®
Insulatard®
Mixtard®
Actrapid®
NovoNorm®
R&D Pipeline
Injection devices
FlexPen®
NovoPen® 4
NovoPen® 3
NovoPen® Junior
InnoLet®
NovoLet®
Innovo®
InDuo®
Needles
NovoFine®
NovoFine® Autocover®
NovoTwist
TM
HypoKit
GlucaGen® HypoKit
Educational resources
GLP-1 in type 2 diabetes
Guidelines
Patient education tools
Slide collection
Levemir®
Treatment regimens
Treatment guidelines
Once daily efficacy
Weight advantage
Improved safety
Starting insulin
PREDICTIVE study
Suitable devices
Toolbox
Prescribing information
Rate this page
Send to a friend
Print
Clinical data
For an overview of the key clinical data
click here
.
Back to top
